OncRef

Clinical Trial: NCT03581630

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

Status:

COMPLETED

Phase:

Not Applicable

Lead Sponsor:Gangnam Severance Hospital
Information Provided By:Gangnam Severance Hospital
Last Update Posted:2018-08-29

Study Overview

Brief Summary

Obesity among breast cancer survivors is known to be associated with recurrence and other co-morbidities. However, there have been no studies on weight reduction program combining diet and anti-obesity drug for obese breast cancer survivors. The purpose of this randomized clinical trial is to examine the effects of Mediterranean Diet and naltrexone/bupropion treatment on inflammation and metabolic risk factors in overweight or obese breast cancer patients after breast cancer treatment.

Official Title

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment on Body Weight and Metabolic Risk Factors in Obese Breast Cancer Patients After Breast Cancer Treatment

Conditions

Breast Cancer, Obesity, Overweight

Intervention / Treatment

  • Drug: naltrexone/bupropion
  • Behavioral: Mediterranean Diet

Other Study ID Numbers

  • 3-2017-0097

Start Date (Actual)

2017-07-29

Primary Completion Date (Actual)

2018-07-22

Study Completion Date (Actual)

2018-07-22

Enrollment (Actual)

72

Study Type

Interventional

Phase

Not Applicable